18 Apr 2016 07:00
Grant of share options to Chief Executive
Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA therapeutics announces the grant of 2,000,000 options over ordinary shares (the "Options") to Chief Executive Ali Mortazavi.
The Options will vest after three years and have an exercise price of 117p, being the closing price on 15 April 2015. The Options are also subject to the price hurdles set out below:
Hurdle to share price (x) | 1.0 | 1.5 | 2.0 | 2.5 | Average |
Share price (p) | 117 | 176 | 234 | 293 | 222 |
Total | |||||
Number of options | 200,000 | 600,000 | 600,000 | 600,000 | 2,000,000 |
These Options are the first options that have been granted to Ali Mortazavi whilst in his role as CEO of Silence.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel | Tel: +44 (0)20 7523 8350 |
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson | Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert | Tel: +44 (0) 20 3727 1000 |
Notes to Editors:
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics.